Myeloid cell kinetics in mice treated with pure hematopoietic growth factors have been investigated using tritiated thymidine labeling and autoradiography. Mice were injected subcutaneously with 125 pg/kg granulocyte colony-stimulating factor (G-CSF) (in some cases 5 pg/kg), or 10 pg/kg of granulocyte-macrophage CSF (GM-CSF), or interleukin-3 (IL-3) every 12 hoursfor 84 hours. 'HTdR labeling was performed in vivo after 3 days of treatment. G-CSF increased the peripheral neutrophil count 14-fold and increased the proportion and proliferation rate of neutrophilic cells in the marrow, suppressing erythropoiesis at the same time. Newly produced mature cells were released into the circulation within 24 hours of labeling, compared with a normal appearance time of about 96 hours. By contrast, GM-CSF and IL-3 had
T tion, and purification of a variety of hematopoietic growth factors have stimulated a number of studies on their effects when used in vivo, both in animals'-' and in patients.6-'0 Treatment of patients or animals with recombinant granulocyte colony-stimulating factor (G-CSF) stimulates a significant neutrophilia with peripheral neutrophils reaching 10 to 15 times their normal level. The effects of granulocyte-macrophage CSF (GM-CSF) are more species specific, enhancing granulocyte levels (neutrophils and eosinophils) by a factor of 3 to 5 in humans' and in nonhuman primates" but not in mice.'* Interleukin-3 (IL-3), likewise, has little effect on mouse peripheral blood cellularity5 but it does stimulate neutrophil production in primate^.'^ There are reports of increased numbers and proliferative activity of progenitor cells (including erythroid burst-forming units [BFU-E]) in the bone marrow of patients treated with GM-CSP while G-CSF has little effect.14 In mice, the major short-term effect of all three factors is to cause a redistribution of both committed progenitor cells and multipotent spleen colony-forming cells from marrow to ~p l e e n~~~*~'~ with IL-3, at least, inducing proliferative activity? Most studies to date have been concentrated on the response of the progenitor cell popula-tions and on the output of mature functional cells. In this study, we have considered the effects on the kinetics of the intermediate amplifying, maturing, and morphologically recognizable cells of polymorphonuclear neutrophil development.
MATERIALS AND METHODS
Female B6D2F, mice aged 9 to 11 weeks were used throughout. Recombinant human G-CSF (rhG-CSF) was kindly supplied by Amgen (Thousand Oaks, CA), recombinant murine GM-CSF (rmGM-CSF) and rmIL-3 by Glaxo (Geneva, Switzerland). G-CSF was used at a dose of 250 kgikg/d (unless othenvise stated). For the preparation used, this dose was equivalent to lo8 U/mg protein. GM-CSF and IL-3 were used at 20 Kg/kg/d (equivalent to 1.25 x 10' and 2.1 x 10' U/mg protein, respectively).
Groups of mice were injected intraveneously (iv) with half the daily dose of growth factor every 12 hours for 84 hours. At daily intervals, three mice from each group were killed by exsanguination from the brachial, arterio-venal complex. From the blood collected, nucleated white cell counts were made and cytospin preparations, stained with May Griinwald/Giemsa, were used for differential cell counts.
After 72 hours of injections of growth factor, tritiated thymidine ('HTdR) was injected, iv (37 kBq/g body weight, 220 GBq/mmol), to the remaining mice. Three mice from each group were killed 1 hour later, their femora excised, and bone marrow suspensions made for each individual animal. Cytospin preparations were made on clean glass slides. Autoradiographs were prepared by dipping the slides in Ilford K5 liquid emulsion and exposing them for 2 weeks before processing. The autoradiographs were stained with May Grunwald/Giemsa. Differential cell counts, percentagelabeled cells, and myeloid cell grain counts were scored, counting a minimum of 500 cells per slide.
Daily peripheral blood preparations (now prepared additionally as autoradiographs) were continued for a further 96 hours with additional points at 3,6,9, and 12 hours after injections of 'HTdR.
A parallel group of normal control mice was processed at each point of obsewation.
RESULTS

Bone Marrow
Differential analyses of the bone marrow are shown in Fig 1 and of labeled cells increased from 48% to 60% in the MB + PMC compartment and from 18% to 29% in the myelocytes. The mean grain count over the proliferating myelocytic cells was increased by 10% to 30% (Table 1) .
Neither GM-CSF nor IL-3 had much effect on either the neutrophilic cell differential or the labeling characteristics. The erythroid populations were maintained and even increased, but at the expense of the lympho/mono-macrophagic population. In the case of G-CSF, the marrow cellularity decreased by about 50% in a redistribution of hematopoiesis between the bone marrow and the spleen," but the increase in the autoradiographic parameters is a measure of the stimulated levels of granulopoiesis in the animals. It may be noted that an additional small-scale study using a dose of 10 pgkg/d G-CSF (for comparison with clinical trial studies) generated a comparable increase in labeling and grain counts without a significant redistribution of cells from the marrow (data not shown).
Blood
In normal mouse blood, about 35% of the 8 x lo6 cells/mL total white cells are neutrophilic granulocytes (polymorphonuclear neutrophils [PMN], 2.8 x lo6/ mL), 60% are lymphocytes, and 5% (0.4 x 106/mL) are monocytes. Repeated injection of G-CSF induced a steady increase in PMN to a maximum of 40 x 106/mL ( Fig 2) . Monocyte numbers increased to 3.1 x 106/mL but there was no change in lymphocyte numbers. Neutrophil numbers rapidly returned to normal within about 3 days of stopping G-CSF treatment. Over the dose schedule and time scale examined, GM-CSF and IL-3 had little effect on the differential constitution of the peripheral blood with PMN numbers reaching only 4.1 x 106/mL and 3.0 x 106/mL, respectively (see Table 2 ).
Labeling with 3HTdR had no effect on the differential constitution of the blood, but in control mice labeled PMN started to appear in the circulation after 24 hours. Numbers increased gradually to a maximum of about 15% labeled after 72 to 96 hours (Fig 3A) . Peak labeling in GM-CSFand IL-3-treated mice occurred only slightly earlier (72 hours) than in control mice, indicating that the kinetics of mature PMN release from the marrow are little different from normal. By contrast, release in the G-CSF-treated Neutrophils. animals was accelerated considerably, with peak labeling of the peripheral cells being seen 24 hours after labeling in the marrow ( Fig 3A) . The numbers of labeled PMN released into the circulation are shown in Fig 3B, illustrating the very large excess production in G-CSF-treated mice. Production was also increased with GM-CSF, but not by IL-3.
The autoradiographic grain counts over the principal population of labeled PMN shown in Fig 3A and B were always in excess of 20 grains and significantly higher than a threshold value of about 5 grains (the upper limit in nonlabeled preparations). A second labeled population with grain counts only marginally above background ( -10 grains) was also evident and recorded separately. These cells are presumed to be the progeny of earlier cells that have undergone more postlabeling maturational divisions before release into the circulation. Figure 4 illustrates the emergence of these cells. Peak neutrophil labeling occurred 72 to 96 hours post-'HTdR injection in G-CSF-treated mice. The other three groups, including the control, all demonstrated comparable kinetics, peaking in labeling at 72 to 96 hours. There is a suggestion from the labeling at 48 hours that GM-CSF may also accelerate the emergence of labeled cells to a small extent. In general, the overall kinetics in this group are unchanged and this early release may indicate a more random release of the newly matured cells than normal.
Labeled cells (3%) were detected in the monocyte fraction in control animals as early as 2 hours after injecting 'HTdR. Between 6 and 9 hours, a wave of labeled cells appeared in the blood. All three growth factors 6) . Data for G should be read on the left hand ordinate; for C, GM, and IL-3 on the right hand ordinate, which has been amplified by a factor of 5.
induced a synchronous and early release of monocytes leading to 40% to 54% labeled cells. This result was followed by an equally rapid decline and labeled cells were cleared from the blood more quickly in the factor-treated mice than in normal mice ( Fig 5) . From the relative numbers and labeling of peripheral monocytes in the period 12 to 24 hours after labeling, IL-3 and GM-CSF cause the release of about twice the normal number of labeled cells while G-CSF increases the number about 17-fold. The error on this figure is large because only about 5% of the population is involved. However, it is clear that G-CSF as well as GM-CSF and IL-3 induces significant numbers of peripheral monocytes.
DISCUSSION
rG-CSF, rGM-CSF, and rIL-3 have been administered by repeated (12 hour) injections over a period of 84 hours to examine marrow hematopoietic activity at the progenitor and/or maturing cell levels. The dose levels chosen were based on previous and were aimed to give a maximal peripheral leucocytosis. However, it should be noted that G-CSF at a dose of 10 pgkg/d (a clinically more relevant dose schedule)6 was equally effective in increasing peripheral leucocyte counts at the early time pointsL5 and comparison of the marrow autoradiographic studies (data not shown) for 10 pgkg/d versus 250 pglkgld showed similar increases in the labeling indices and grain counts. The results obtained, therefore, are probably realistic indicators of the effects of these growth factors on myeloid cell kinetics. The results confirm that G-CSF induces a considerably increased production of circulating PMN that, as shown by the human studies, are functionally normal." GM-CSF generates only a small increase and this is contrary to its effect in human studies where four to five times the normal levels of PMN are generated.' In the same way, IL-3 generates a modest increase in PMN of nonhuman prim a t e~'~ but, as in our earlier studies, failed to stimulate PMN production in mice."
Hours post3 HTdR
The effects of G-CSF on the marrow agreed remarkably well with those reported for humans," viz, an increase in proportion and labeling of the earlier myeloid forms, increased labeling (but not proportion) of myelocytes, and an increase in the proportion of metamyelocytes (Fig 1,  Table 1 ). Under steady-state conditions, for a population of proliferating cells, the labeling index: To make comparisons of the cell cycle parameters with the various growth factor treatments, we have assumed an average control value of 5 hours for t, in mice. Thus, for control mice, the cycle time is given by t, = 5/I, so that, for example, for all proliferative neutrophilic cells with I, = 0.26, the mean cell cycle time is 19.2 hours (Table 1) .
Because the grain count over labeled cells is proportional to the rate of DNA synthesis (Uts), for animals treated with G-CSF the increase in grain count from 77 to 95 indicates a shortening of t,, proportionately, to 4.1 hours. With an increase also in the labeling index from 0.26 to 0.38 in this group, the comparative t, is reduced to 10.9 hours (Table 1) .
Combining the increased labeling indices and grain counts in this way, it is clear that the mean cycle times of the maturing neutrophilic cells under G-CSF treatment are reduced by about 25% to 40% (Table 1) .
A further indication of the reduced cell cycle times is obtained by comparing the times of appearance of strongly (40 grains/cell) and weakly (10 grains/cell) labeled cells in the peripheral blood. Considering this grain count dilution to be the result of approximately two division cycles, it can be seen from Fig 6 that the 50% peak labeling values are about 17 hours apart, suggesting an average cycle time of 8.5 hours. This time is of the same order as that calculated from the marrow labeling (Table 1) .
As with the human study, the lack of increase in the proportion of myelocytes, despite the more rapid proliferation, indicates that the overall maturation time is reduced, with the major amplification in the population arising in the earlier stages. The 50% increase in myeloblasts and promyelocytes was translated to only a 29% increase in the total granulocytic population, suggesting early release of mature cells. It is this more rapid maturation and release that results in their early appearance in the circulation. Measuring the 50% of peak appearance times (Fig 3) in the blood, it is clear that mature, functional neutrophils are available in the circulation 35 to 40 hours earlier than normal.
The lack of any measurable effect of either IL-3 or GM-CSF on marrow cell kinetics is perhaps more surprising. In humans (ref 9 and our own data, submitted) GM-CSF increases the proliferative activity of the maturing granulocytic cells in the marrow and increases neutrophil output into the circulation by a factor of four to five compared with less than 50% increase in this study. Compared with G-CSF, where erythroid differentiation was severely depressed (Fig l) , IL-3 and particularly GM-CSF increased the proportion of erythroid cells slightly, and this is consistent with the earlier report9 that GM-CSF in humans stimulates also the erythroid progenitor cells.
The principles of analyzing peripheral blood cell kinetics using 'HTdR were established in the late 1950s for normal Using a similar approach, it is possible to make an assessment of the relative neutrophil production rates resulting from these growth factor treatments.
The half-lives (tm) of the peripheral neutrophils are calculated from the rate of loss of labeled cells in the blood, using the formula N = Nee-", where No = peak number of cells, N = number of cells at time t, and A = the decay constant. Thus, for G-CSF ( Fig 3B) , No = 100 at 24 hours, N = 18 at 48 hours. Then A (from 18 = 100 = 0.0714 and t,,, given by 1 = 2e-0.07L4.t1n = 9.7 hours. Similarly for GM-CSF and IL-3, t,, = 8.3 hours ( Table 2 ). The data for the descending arm of the control curve were not sufficiently well defined to make a similar calculation. In humans, G-CSF had no effect on the half-life." Consequently, a value of 8 hours (similar to that for humans) has been assumed here. None of these growth factors thus appear to affect the peripheral half-life of PMN.
Taking the increase in neutrophils over 24 hours after labeling and correcting for the loss over the same period due to their peripheral half-life, one can estimate the true increase in numbers and, hence, calculate the excess production over normal. (In normal mice, a steady state exists and the rate of production equals the rate of loss). For example, with G-CSF, the PMN increase from 24.8 x 106/mL to 40 X 106/mL between 72 and 96 hours, an increase over 24 hours of 15.2 x 106/mL. With t,,2 = 9.7 hours and A = 0.0714, the loss of cells over the same period would be given by: n = 24.8 x e-0.0714xza = 4.5; a loss of 20.3 X lo6 cells/mL. Net production is therefore equal to (15.2 + 20.3) x lo6 = 35.5 x 106/mL. By comparison, in the controls, given that t,, = 8 hours, A = 0.0866 so that over 24 hours, 2.8 x IO6 cells/mL would become 0.35 x lo6, a loss of 2.45 x 106/mL.
The amplification factor for G-CSF over control ( Table  2) is therefore given by 35.5 X 106/2.45 X lo6 = 14.5 and this is achieved by incorporating 3.8 extra amplification divisions into the neutrophil production sequence. This value compares well with the 3.2 extra divisions calculated from the human data."
Bearing in mind the large number of division cycles between the early stem and final mature cell stages, this is a very modest increase and as such is unlikely to inflict any serious drain on the stem and progenitor compartments. The modest increases in neutrophil production as a result of GM-CSF or IL-3 treatment were 0.6 and 0.1 extra amplification divisions only ( Table 2 ).
It appears, therefore, that G-CSF affects myelopoiesis similarly in both humans and mice. On the other hand, in contrast to the effects of human GM-CSF in humans,' mGM-CSF and mIL-3 have little overall effect on murine myelopoiesis in vivo.
The emergence of normal labeled monocytes in the first day after labeling, followed by a slow rate of disappearance from the blood (Fig 5) , is in good agreement with the original observations of Cronkite et all6 in humans. From our measurements, the peripheral half-life of these monocytes is about 60 hours (Table 3) . A rough calculation from the data presented by Cronkite et all6 gives a figure of about 46 hours for humans. The higher figure, perhaps representing a lower state of functional activation, may reflect the more protected environment of a laboratory animal. Appearing at least as quickly as in normal mice, and in nearly eight times the normal number, monocytes in G-CSF-treated mice have a more sharply defined removal profile with a peripheral half-life of only 6.5 hours (Table 3 ). Though not seen in a phase 1/11 human study by Bronchud et a1,6 in For personal use only. on September 14, 2017. by guest www.bloodjournal.org From primates by Welte et a1,' or in hamsters by Cohen et al,3 a comparable increase (sevenfold) was observed by Morstyn et a17 in humans treated with 10 pg,kg/d G-CSF.
The increase in monocytes in GM-CSF and IL-3-treated mice is in line with the increase in neutrophils, indicating at least dual effectiveness at the progenitor level. That they also have reduced peripheral half-lives (tl,z = 23.3 and 15.1 hours, respectively; Table 3 ) is also interesting, but in agreement with earlier observations, at least for GM-CSF, which has been shown to be a potent stimulator of peritoneal macrophages."
Calculations of monocyte production show that growth factor effects on their development are at least as significant as for neutrophil production. For all three factors, the peripheral half-life is considerably shortened. This shortening may be due to sequestration and use in the tissues. Nevertheless, simply to maintain peripheral numbers, let alone increase them, their production rate must be increased. Table 3 shows the relevant parameters as calcu-lated from the labeling data and it is clear that nearly 5 extra amplification divisions are required to generate and maintain the appropriate number of monocytes. At this level of activity it is tempting to speculate on whether the balance of self-renewal and differentiation of the progenitor might be swung to allow a greater input into the macrophage lineage (at the expense of maintaining the progenitor pool). With GM-CSF in which nearly 2 extra divisions are required, there is clearly no problem. Indeed, under long-term administration of GM-CSF all the marrow progenitor and cellularity parameters become normalized." The effects of long-term G-CSF treatment, however, are not yet known.
